Celularity Inc (CELU) Stock Price, Quote & News

Company Profile

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and deg...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 768 2170

Website: www.celularity.com

Address:

170 Park Avenue, Florham Park, United States

Zephix Aug. 18 at 7:09 PM

$CELU looking great

0 · Reply

vieketo Aug. 18 at 6:45 PM

$CELU why up?

0 · Reply

Zephix Aug. 18 at 3:06 PM

$CELU BUULLLISH

0 · Reply

luckydog2 Aug. 18 at 3:17 AM

$CELU

0 · Reply

luckydog2 Aug. 17 at 1:11 AM

$CELU https://www.reddit.com/r/CelularityNews/s/fqg42nRSqj

2 · Reply

NuclearMan Aug. 14 at 8:14 PM

$CELU The 10Q for Q2 has also just been notified as late. Again the justification is "liquidity issues". ie. ash runway. This is still as what happened in 2025 but no Nasdaq extension granted yet...

1 · Reply

NuclearMan Aug. 14 at 3:30 PM

$CELU One more thing. The Barach loan is can be interpreted as a mechanism that stops any outside entity scooping the stock for pennies on the dollar. He has his own investment and ALSO has that loan which gives him priority over assets. It is not worthwhile for an outside entity to short this and buy the stock from OTC. A kind of "poison pill" if you know trading jargon.

0 · Reply

NuclearMan Aug. 14 at 3:28 PM

$CELU One frustration that caught me out was because we did not get the Q1 when financing came in. I assumed the Nexgel sale would give CELU a runway to pay CFO Squad (who filed the 10K), but I was gambling blind because we had no 10Q. And it seems the money was allocated elsewhere. So I then went back so see what was going on and as I say below, Bob makes a conscious decision to prioritise. So we are currently stuck. But FWIW I do think there is a chance this works out

0 · Reply

NuclearMan Aug. 14 at 3:22 PM

$CELU The competency issue raised is valid, but Bob isn't running a chaotic ship. Past analysis says he pulls funding from 10Q filings (which are expensive) when the cash runway gets tight. We can be annoyed at this for sure, but it is a business choice rather than because he's on a yacht. And believe me I did wonder myself lol. The financials historically bear out what I'm saying though.

0 · Reply

NuclearMan Aug. 14 at 3:19 PM

$CELU There should be a ruling from Nasdaq on the late 10Qs tonight or next week. I'd still guess both Q1 and Q2 arrive at the end of the month. The MMs have pulled liquidity which is why the spread is so wide. It is the standard mechanism to keep the price fixed. The order book is totally hollow rn. We need to get through Friday AH filings unscathed. Then 90% chance of Nasdaq giving a ruling next week. This type of appeal never usually goes much longer than that.

0 · Reply

Penny Stocks: Why Is Celularity (CELU) Stock Trending Today?

NXGL

2026-06-04T12:20:25.000Z - 2 months ago

Celularity announces cenplacel-L availability for investigational use in Florida

Jun 4, 2026, 8:00 AM EDT - 2 months ago

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Jun 3, 2026, 4:15 PM EDT - 2 months ago

Celularity Releases CEO Letter to Shareholders

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

May 29, 2026, 5:15 PM EDT - 2 months ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

May 1, 2026, 4:30 PM EDT - 3 months ago

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

Apr 30, 2026, 7:00 AM EDT - 3 months ago

Celularity Annual report: Q4 2025

Apr 27, 2026, 9:00 AM EDT - 4 months ago

NEXGEL Appoints Ian Blackman as Chief Financial Officer

2026-04-21T15:06:20.000Z - 4 months ago

NexGel closes acquisition of products from Celularity

NXGL

2026-04-21T13:07:46.000Z - 4 months ago

Celularity announces closing of transaction with NexGel

Apr 21, 2026, 8:30 AM EDT - 4 months ago

Celularity Announces Closing of Transaction with NexGel

Apr 17, 2026, 4:35 PM EDT - 4 months ago

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

2026-03-12T12:55:45.000Z - 5 months ago

NexGel announces terms of agreement of license for products from Celularity

NXGL

2026-03-12T12:35:15.000Z - 5 months ago

Celularity reiterates strategic commercialization partnership with NEXGEL

NXGL

Mar 12, 2026, 8:30 AM EDT - 5 months ago

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

2026-03-10T12:51:55.000Z - 5 months ago

NexGel sign agreement to license, acquire portfolio of products from Celularity

NXGL

2026-03-10T12:41:03.000Z - 5 months ago

Celularity secures $35M strategic license deal

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

2026-02-10T13:41:35.000Z - 6 months ago

Celularity receives $12.2M from sale of New Jersey net operating losses

Feb 10, 2026, 8:30 AM EST - 6 months ago

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

2025-12-31T21:20:16.000Z - 8 months ago

Celularity files to sell 14.08M shares of Class A common stock for holders

Dec 31, 2025, 7:00 AM EST - 8 months ago

Celularity Registration statement: Registration Filing

Dec 26, 2025, 8:30 AM EST - 8 months ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

Dec 22, 2025, 4:01 PM EST - 8 months ago

Celularity Announces Closing of Financing Transactions

2025-12-19T21:20:21.000Z - 8 months ago

Celularity files to sell 15.95M shares of Class A common stock for holders

Dec 19, 2025, 7:00 AM EST - 8 months ago

Celularity Registration statement: Registration Filing

2025-12-18T19:15:11.000Z - 8 months ago

Celularity announces up to $12M of capital from Philip Barach

Dec 18, 2025, 2:10 PM EST - 8 months ago

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Nov 14, 2025, 7:00 AM EST - 9 months ago

Celularity Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

Celularity Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

Celularity Proxy statement: Proxy Filing

2025-10-30T12:20:52.000Z - 10 months ago

Celularity, DefEYE partner to advance regenerative therapies in eye care

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

2025-10-14T12:55:36.000Z - 11 months ago

Celularity announces publication of Phase 2 study on PDA-002

Oct 14, 2025, 8:45 AM EDT - 11 months ago

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

2025-09-03T12:10:50.000Z - 1 year ago

Celularity reports Q1 EPS (84c) vs ($1.03) last year

2025-09-03T12:10:44.000Z - 1 year ago

Celularity regains compliance with Nasdaq listing rule

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Aug 29, 2025, 9:30 AM EDT - 1 year ago

Celularity Quarterly report: Q2 2025

Aug 29, 2025, 12:00 AM EDT - 1 year ago

Celularity Quarterly report: Q1 2025

2025-08-22T21:35:07.000Z - 1 year ago

Celularity receives noncompliance notice from Nasdaq

2025-08-18T12:20:27.000Z - 1 year ago

Celularity completes balance sheet restructuring, retires $41.6M in debt

Aug 18, 2025, 8:00 AM EDT - 1 year ago

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

2025-07-01T12:40:49.000Z - 1 year ago

Celularity hails new Florida law opening patient access to stem cell therapies

Jul 1, 2025, 8:30 AM EDT - 1 year ago

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Jun 10, 2025, 4:15 PM EDT - 1 year ago

Celularity Announces Chief Financial Officer Transition

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

May 9, 2025, 4:00 PM EDT - 1 year ago

Celularity Earnings release: Q4 2024

May 9, 2025, 4:00 PM EDT - 1 year ago

Celularity Annual report: Q4 2024

May 9, 2025, 9:15 AM EDT - 1 year ago

Celularity Announces Full Year 2024 Operating and Financial Results

Apr 25, 2025, 5:30 PM EDT - 1 year ago

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Feb 25, 2025, 8:00 AM EST - 1 year ago

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Feb 24, 2025, 8:00 AM EST - 1 year ago

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Feb 13, 2025, 7:00 AM EST - 1 year ago

Celularity Registration statement: Registration Filing

Jan 30, 2025, 7:00 AM EST - 1 year ago

Celularity Registration statement: Registration Filing

Dec 10, 2024, 8:00 AM EST - 1 year ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 6, 2024, 8:00 AM EST - 1 year ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Dec 5, 2024, 6:00 PM EST - 1 year ago

Celularity Quarterly report: Q3 2024

Nov 27, 2024, 5:00 PM EST - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 20, 2024, 8:30 AM EST - 1 year ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Nov 19, 2024, 7:00 AM EST - 1 year ago

Celularity Proxy statement: Proxy Filing

Nov 6, 2024, 6:00 PM EST - 1 year ago

Celularity Quarterly report: Q2 2024

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 18, 2024, 6:00 PM EDT - 1 year ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 16, 2024, 5:15 PM EDT - 1 year ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Oct 16, 2024, 3:30 AM EDT - 2 years ago

Celularity Quarterly report: Q1 2024

Sep 5, 2024, 4:05 PM EDT - 2 years ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 28, 2024, 4:45 PM EDT - 2 years ago

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 23, 2024, 5:00 PM EDT - 2 years ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Jul 31, 2024, 8:30 AM EDT - 2 years ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Celularity Annual report: Q4 2023

Jun 3, 2024, 8:38 AM EDT - 2 years ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 21, 2024, 12:00 PM EDT - 2 years ago

Celularity Transcript: Analyst Research & Development Day 2024

May 21, 2024, 12:00 PM EDT - 2 years ago

Celularity Slides: FY 2024

May 14, 2024, 9:15 AM EDT - 2 years ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 19, 2024, 5:30 PM EDT - 2 years ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 18, 2024, 4:30 PM EDT - 2 years ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 8, 2024, 9:00 AM EDT - 2 years ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Mar 26, 2024, 9:00 AM EDT - 2 years ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 20, 2024, 9:15 AM EDT - 2 years ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 14, 2024, 9:15 AM EDT - 2 years ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 12, 2024, 9:20 AM EDT - 2 years ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 7, 2024, 9:35 AM EST - 2 years ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Zephix Aug. 18 at 7:09 PM

$CELU looking great

0 · Reply

vieketo Aug. 18 at 6:45 PM

$CELU why up?

0 · Reply

Zephix Aug. 18 at 3:06 PM

$CELU BUULLLISH

0 · Reply

luckydog2 Aug. 18 at 3:17 AM

$CELU

0 · Reply

luckydog2 Aug. 17 at 1:11 AM

$CELU https://www.reddit.com/r/CelularityNews/s/fqg42nRSqj

2 · Reply

NuclearMan Aug. 14 at 8:14 PM

$CELU The 10Q for Q2 has also just been notified as late. Again the justification is "liquidity issues". ie. ash runway. This is still as what happened in 2025 but no Nasdaq extension granted yet...

1 · Reply

NuclearMan Aug. 14 at 3:30 PM

0 · Reply

NuclearMan Aug. 14 at 3:28 PM

0 · Reply

NuclearMan Aug. 14 at 3:22 PM

0 · Reply

NuclearMan Aug. 14 at 3:19 PM

0 · Reply

Nosay Aug. 13 at 6:08 PM

$CELU well $NXGL is going up. We’re very positively affected if they’re doing good. If we can get our q1 and q2 filed we should start taking off. Unfortunately our leaders are MIA and completely incompetent at basic filings and accounting.

0 · Reply

NuclearMan Aug. 12 at 3:43 PM

$CELU Anyway, if we follow last year, we are expecting the Nasdaq ruling on the 10Q extension any time now. If they approve an extension to end Aug, we may see another warning for the Q2 financials and then BOTH filed a couple of days before the deadline. Presumably the Barach loan funded CFO Squad to do this. When we see financials, much will be clearer (Assuming/hoping it all works out).

0 · Reply

NuclearMan Aug. 12 at 3:39 PM

$CELU The counterpoint to my post below is that Bob has gambled on something and it hasn't worked out. That would be verrrry bad. And he has played a very very risky game with the cash runway. If Helena had still been involved they would have pulled the plug. But Barach hasn't called in his loan yet. It's a weird one. Probably resolves in a very binary way.

0 · Reply

NuclearMan Aug. 12 at 3:34 PM

$CELU Here's something to consider. Remember when Hariri issued the shareholder letter? At that moment he could have tapped the ATM and solved a lot of issues. Instead he elected for non-dilutive stuff to keep the common stock, Robbins, Diamandis and Barach intact. Now he cannot use the ATM due to noncompliance. That implies there is some "plan".

0 · Reply

KingStocks1 Aug. 11 at 4:39 PM

$CELU Hariri starting to look like a fraud sadly… zero updates in over a year. Tanking. Shareholders just stuck clueless with no consequences for the company

1 · Reply

NuclearMan Aug. 11 at 1:24 PM

$CELU Forgot to say; last year CELU published that Nasdaq had granted them a 31st August deadline on 12th August 2025. Today is 11th.

0 · Reply

NuclearMan Aug. 11 at 1:17 PM

$CELU If this helps, here is the timeline for last year's delinquent 10Qs.

1 · Reply

NuclearMan Aug. 8 at 7:36 AM

$CELU PS regarding the below I kicked these back and forth with Gemini for a while so I haven't just made them up lol. It weighed the probabilities and settled on scenario 1 because of the wording and the timing of the filing. It also said this was not a critical market mover because the market is looking at the short term comploance and cash runway and the medium term non-dilutive partnership. The problem is this prolonged dark period gives us so little to go on other than things like this 8K.

0 · Reply

NuclearMan Aug. 8 at 7:30 AM

$CELU Terminating the CCO hired 70 days ago is weird. There are three scenarios. 1) The 8k did not have the typical "no dispute" wording. He may have been fired because he didnt share Bob' views and did not get thru his probationary period. Most likely. 2) CELU is partnering with a big entity who want total conttol of the commercial side. Possible. 3) CELU cannot afford to keep him. Least likely because the cash runway etc were known when he was hired.

0 · Reply

dostephe Aug. 7 at 10:47 PM

$CELU A few weeks ago, CELU hired a new Chief Commercial Officer. Today they fired him. What the hell is Hariri doing???

1 · Reply

NuclearMan Aug. 7 at 4:51 PM

$CELU One more thing. Celularity previously filed two 10Qs on the same day. Q1 and Q2 of 2025 were filed simultaneously at the end of August. We may have a similar situation here. Just speculation, but it's the same scenario. A late Q1 10Q, a Nasdaq plan, and a clock ticking for Q2 at the end of August. That's all I've got, but we may see the Nasdaq plan accepted and then two 10Qs in the next two weeks or so.

1 · Reply

NuclearMan Aug. 7 at 4:45 PM

$CELU BTW assuming they filed the Nasdaq plan for filing the 10Qs (which I think we can assume, because they said they planned to and have not contradicted that), then a ruling could be next week. The "plan" is basically they had to prove they could fund CFO Squad. So that ruling may tell us what CELU cannot.

0 · Reply

Market Cap	20.15M
Revenue (ttm)	26.55M
Net Income (ttm)	-91.72M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-345.46%
Debt to Equity Ratio	-1.26

Volume	72,800
Avg Vol	99,104
Day's Range	N/A - N/A
Shares Out	28.95M
Stochastic %K	47%
Beta	0.54
Analysts	Sell
Price Target	$6.00